Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FALCO SD: Dispensing Pharmacy Business Drives Business
June 14, 2010
- Astellas Successfully Completes Tender Offer for OSI
June 14, 2010
- Rohto: Increases in Sales for 17 Straight Years
June 14, 2010
- Falco SD Aims at Sales of ¥70.0 Bil. in FY2013
June 14, 2010
- Banyu Aims at 16% Market Share for Cosopt
June 14, 2010
- Sanofi-aventis Nichi-Iko to Consider Marketing of Authorized Generics
June 14, 2010
- Transnasal GLP-1 Improves Blood Glucose Control
June 14, 2010
- Bayer to Enhance Its Presence in Dermatology
June 14, 2010
- New Taiyo Yakuhin May Consider IPO: President Aratani
June 14, 2010
- Miraka HD: Sales Up 2.6% to ¥149,074 Mil.
June 14, 2010
- CMIC: Half-Year Sales Up 12.7% to ¥16 Bil.
June 14, 2010
- Nihon Chouzai to Open 30 Pharmacies Downtown
June 14, 2010
- Takara's Technology Supports Bio Research in Japan: President Ohmiya
June 14, 2010
- MSNW: Dispensing Pharmacy Business Boosts Sales, Profits
June 14, 2010
- Kyowa Kirin Licenses KW-6002 to BLS in North America
June 14, 2010
- JDS HbA1c Values to Be Replaced with NGSP HbA1c Values
June 14, 2010
- Astellas to Copromote Kaketsuken's Vaccines in Kyushu
June 14, 2010
- Novartis to Drive Business by Expanding Range of Indications for Afinitor: Mr Asakawa
June 14, 2010
- Naoto Kan Elected 94th Prime Minister of Japan
June 14, 2010
- DSP, JCR Sign Assignment Agreement for Growth Hormone Business
June 14, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…